Cargando…
Changes in labelling for metformin use in patients with type 2 diabetes and heart failure: documented safety outweighs theoretical risks
Autores principales: | Eurich, Dean T, Majumdar, Sumit R, McAlister, Finlay A, Tsuyuki, Ross T, Johnson, Jeffrey A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Open Medicine Publications, Inc.
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3205816/ https://www.ncbi.nlm.nih.gov/pubmed/22046218 |
Ejemplares similares
-
Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality
por: Eurich, Dean T, et al.
Publicado: (2009) -
Analyzing composite outcomes in cardiovascular studies: traditional Cox proportional hazards versus quality-of-life–adjusted survival approaches
por: Eurich, Dean T, et al.
Publicado: (2010) -
A cluster randomized trial to assess the impact of opinion leader endorsed evidence summaries on improving quality of prescribing for patients with chronic cardiovascular disease: rationale and design [ISRCTN26365328]
por: Majumdar, Sumit R, et al.
Publicado: (2005) -
Treated glycosylated hemoglobin levels in individuals with diabetes mellitus vary little by health status: A retrospective cohort study
por: McAlister, Finlay A., et al.
Publicado: (2016) -
The preventing recurrent vascular events and neurological worsening through intensive organized case-management (PREVENTION) trial protocol [clinicaltrials.gov identifier: NCT00931788]
por: McAlister, Finlay A, et al.
Publicado: (2010)